8-K: Enhabit Reports Q2 Growth, Debt Reduction Amid Industry Challenges

Enhabit, Inc. highlights Q2 2025 financial improvements, significant debt reduction, and strong hospice growth while addressing home health industry pressures.

Summary

• Enhabit, Inc. reported Q2 2025 net income of $5.7 million, a substantial increase from $0.4 million in Q2 2024.
• Consolidated net service revenue grew 2.1% year-over-year and 2.4% sequentially to $266.1 million.
• Adjusted EBITDA increased 6.7% year-over-year and 1.2% sequentially to $26.9 million.
• The company reduced bank debt by $10.0 million in Q2 2025, bringing total bank debt reduction to $70.0 million since Q1 2024.
• The leverage ratio decreased to 4.3x as of June 30, 2025, down from 4.9x at December 31, 2024.
• Annualized cash interest expense was reduced by $17.2 million (-34%) from Q4 2023 to Q2 2025.
• Hospice segment demonstrated consistent growth with a 6th straight quarter of sequential average daily census (ADC) growth and double-digit year-over-year growth.
• Home Health segment showed a 2nd quarter of sequential growth in net service revenue and Adjusted EBITDA, with stabilized Medicare ADC.
• Enhabit successfully renegotiated a national payer agreement for home health, resulting in a low double-digit percentage rate increase.
• The company opened 3 new de novo sites in Q2, bringing the year-to-date total to 4, and remains on track to meet its goal of 10 in 2025.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive, reflecting significant improvements in consolidated financial metrics, strong hospice growth, and effective debt reduction. However, the home health segment experienced a year-over-year decline in revenue and margin, and the company faces ongoing industry-wide challenges like proposed Medicare cuts, which temper overall enthusiasm.

Positives

• Consolidated net income significantly increased to $5.7 million in Q2 2025 from $0.4 million in Q2 2024.
• Consolidated Adjusted EBITDA grew 6.7% year-over-year and 1.2% sequentially to $26.9 million.
• Total debt was reduced by $85 million since Q4 2023, with $10 million in prepayments in Q3 2025.
• Leverage ratio improved to 4.3x as of June 30, 2025, a decrease of 1.1 turns from Q4 2023.
• Annualized cash interest expense decreased by $17.2 million (-34%) from Q4 2023 to Q2 2025.
• Hospice segment reported strong performance with 12.3% year-over-year ADC growth and 53.8% year-over-year Adjusted EBITDA increase.
• Home Health segment achieved sequential growth in net service revenue (2.6%) and Adjusted EBITDA, with Medicare ADC stabilization.
• A national payer agreement for home health was successfully renegotiated, securing a low double-digit rate increase.
• The company is on track to open 10 de novo locations in 2025, having opened 4 year-to-date.

Negatives

• Home Health net service revenue decreased year-over-year to $205.9 million in Q2 2025 from $210.2 million in Q2 2024.
• Home Health Segment Adjusted EBITDA decreased year-over-year to $39.3 million in Q2 2025 from $44.2 million in Q2 2024.
• Home Health Segment Adjusted EBITDA margin declined year-over-year to 19.1% in Q2 2025 from 21.0% in Q2 2024.
• National home health agencies count (excluding California) has declined by 13.6% from 2019 to 2024.

Risks

• Ability to execute on strategic plans.
• Regulatory and other developments impacting the markets for services, including proposed Medicare cuts to home health.
• Changes in reimbursement rates.
• General economic conditions.
• Changes in the episodic versus non-episodic mix of payers, patient case mix, and payment methodologies.
• Ability to attract and retain key management personnel and healthcare professionals.
• Potential disruptions or breaches of information systems (company, vendors, payers, contract counterparties).
• Outcome of litigation.
• Quality performance and ratings.
• Ability to successfully complete and integrate de novo locations, acquisitions, investments, and joint ventures.
• Ability to successfully integrate technology in operations.
• Ability to control costs, particularly labor and employee benefit costs.

Future Outlook

The company's 2025 priorities include continuing home health momentum, consistent hospice growth, opening 10 de novo locations in strategic markets, optimizing de novo locations opened in 2023 and 2024, continuing to de-leverage the balance sheet, managing G&A expenses, and improving various operational metrics such as cost per patient day, revenue per patient day, value-based performance, patient experience, readmission rates, visits in the last days of life, engagement, retention, business development direct selling headcount, and leadership development.

Management Comments

• We are focused on home health momentum, which delivered a second quarter of sequential growth in net service revenue and Adjusted EBITDA, while continuing to stabilize Medicare ADC.
• Hospice has shown consistent growth with its sixth straight quarter of sequential ADC growth and double-digit growth compared to the prior year.
• We successfully re-negotiated a national payer agreement for home health, resulting in a low double-digit percentage rate increase.
• De novo growth is on track with 3 new sites in Q2, bringing the year-to-date total to 4, aiming for 10 in 2025.
• Consistent de-levering has resulted in a fifth straight quarter of debt prepayments, totaling $45 million since Q1 2024, lowering interest expense by $3.2 million over the same period.

Industry Context

The healthcare industry is experiencing significant tailwinds driven by an aging population, with 75% of those aged 50 and over desiring to stay in their residence as they age. Home health care offers a cost-efficient alternative, being 10 times lower cost than other care settings, with Medicare costs per day significantly lower than skilled nursing facilities. The addressable markets for Medicare skilled home health and hospice expenditures are large and growing, projected at ~$41 billion and ~$32 billion respectively by 2028. The industry is actively advocating against proposed Medicare cuts to home health, with bipartisan legislation (HR 5142, the Home Health Stabilization Act) introduced to pause cuts for CYs 2026 and 2027. Access to home health is crucial, as its absence leads to a 41% increase in mortality rate, 34% increase in readmissions, 16% increase in ER visits, and a ~$2,500 increase in total cost of care for Medicare beneficiaries.

Comparison to Industry Standards

• The filing highlights that home health care is 10x lower cost than other care settings, with average Medicare cost per day at $63 for home health compared to $556 for Skilled Nursing Facilities (SNF) and $186 for Hospice, based on MedPAC reports.
• It notes that 75% of those aged 50 and over want to stay in their residence as they age, according to an AARP 2024 Survey, indicating strong patient preference for home-based care.
• The document discusses the national decline in home health agencies (excluding California), contrasting it with significant growth in California, but does not provide specific comparisons of Enhabit's performance metrics against direct competitors or industry averages for revenue growth or profitability.

Legal Proceedings

• The company mentions 'nonroutine litigation' and 'third-party legal and advisory fees related to shareholder and non-shareholder matters' as unusual or nonrecurring items impacting Adjusted EBITDA calculations in Q2 2025 and prior periods.

Stakeholder Impact

• Shareholders: Positive impact from increased net income, Adjusted EBITDA, and significant debt reduction, potentially leading to improved shareholder value.
• Employees: Positive impact from an 'award-winning culture' and strategic advantage in attracting and retaining talent, along with advocacy efforts against Medicare cuts that could protect jobs.
• Patients: Continued focus on providing 'superior, cost-effective care' and improving patient outcomes, experience, and reducing readmission rates.
• Payers and Health Systems: Strengthened relationships as a 'trusted partner' through high-quality outcomes and successful payer agreement renegotiations.
• Creditors: Positive impact from consistent debt reduction and improved leverage ratio, indicating stronger financial health and reduced credit risk.

Next Steps

• Participate in a fireside chat at the Jefferies 2025 Healthcare Services Conference on September 30, 2025.
• Continue to open de novo locations in strategic markets, aiming for a total of 10 in 2025.
• Optimize de novo locations opened in 2023 and 2024.
• Continue de-leveraging the balance sheet through debt prepayments.
• Focus on G&A expense management.
• Improve home health and hospice cost per patient day and home health revenue per patient day.
• Enhance value-based performance, patient and family experience, home health hospital readmission rates, and hospice visits in the last days of life.
• Strengthen employee engagement, retention, business development direct selling headcount, and leadership development.

Key Dates

Recommendation

The company demonstrates strong progress in debt reduction, improved overall profitability, and robust growth in its hospice segment. These factors suggest a positive trajectory. However, the home health segment experienced a year-over-year decline in revenue and Adjusted EBITDA margin, and the company faces ongoing regulatory risks related to proposed Medicare cuts. While the management's strategic priorities and execution show promise, the mixed performance across segments and external pressures warrant a 'hold' recommendation, allowing investors to observe sustained improvements in the home health segment and the resolution of regulatory uncertainties before a more aggressive stance.

Keywords

Enhabit, Home Health, Hospice, Healthcare Services, Financial Results, Adjusted EBITDA, Debt Reduction, SEC Filing, Investor Presentation, Jefferies Conference, Medicare, De Novo Growth